Thalomid® May not Improve Outcomes of Patients with Small-Cell Lung Cancer (SCLC)
Researchers from the UK have reported that the addition of Thalomid to etoposide plus Paraplatin (carboplatin) did not improve outcomes of patients with advanced small cell lung cancer SCLC). The details of this randomized trial were presented at the Presidential Symposium of the 12th World Conference on Lung Cancer in Seoul, Korea, September 2-6, 2007.
This entry was posted on Monday, October 22nd, 2007 at 3:41 pm and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.